Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Len Neckers

Showing results (81-90 of 168) with videos related to

Pageof 17
Sort By:
Advances in Cancer Research|February 27, 2016
Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 InhibitorsMark R Woodford, Diana Dunn, Jonelle B Miller, et al.
The Biochemical Journal|December 14, 2002
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activationYunJin Jung, Jennifer S Isaacs, Sunmin Lee, et al.
Journal of the American Chemical Society|November 30, 2006
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90Joseph A Burlison, Len Neckers, Andrew B Smith, et al.
EMBO Reports|May 9, 2006
Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNKQingfeng Yang, You-Sun Kim, Yong Lin, et al.
Molecular Cancer Research : MCR|May 16, 2025
Mitochondrial HSP90 paralog TRAP1 deletion drives glutamine addiction in tumor cells via destablization of the Cys/Glu antiporter SLC7A11/xCTAbhinav Joshi, Li Dai, Marisa Maisiak, et al.
Journal of Proteome Research|October 11, 2005
Direct identification of ubiquitination sites on ubiquitin-conjugated CHIP using MALDI mass spectrometryDongxia Wang, Wanping Xu, Sara C McGrath, et al.
Future Medicinal Chemistry|June 6, 2013
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivityAnnerleim Walton-Diaz, Sahar Khan, Dimitra Bourboulia, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2006
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activationFumitaka Koga, Wanping Xu, Tatiana S Karpova, et al.
International Journal of Cancer|October 4, 2011
Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cellsManabu Tatokoro, Fumitaka Koga, Soichiro Yoshida, et al.
Current Topics in Medicinal Chemistry|April 14, 2016
Targeting Hsp90 in Non-Cancerous MaladiesMark R Woodford, Diana M Dunn, Joseph G Ciciarelli, et al.
Pageof 17

Showing results (81-90 of 168) with videos related to

Sort By:
Pageof 17
Advances in Cancer Research|February 27, 2016
Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 InhibitorsMark R Woodford, Diana Dunn, Jonelle B Miller, et al.
The Biochemical Journal|December 14, 2002
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activationYunJin Jung, Jennifer S Isaacs, Sunmin Lee, et al.
Journal of the American Chemical Society|November 30, 2006
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90Joseph A Burlison, Len Neckers, Andrew B Smith, et al.
EMBO Reports|May 9, 2006
Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNKQingfeng Yang, You-Sun Kim, Yong Lin, et al.
Molecular Cancer Research : MCR|May 16, 2025
Mitochondrial HSP90 paralog TRAP1 deletion drives glutamine addiction in tumor cells via destablization of the Cys/Glu antiporter SLC7A11/xCTAbhinav Joshi, Li Dai, Marisa Maisiak, et al.
Journal of Proteome Research|October 11, 2005
Direct identification of ubiquitination sites on ubiquitin-conjugated CHIP using MALDI mass spectrometryDongxia Wang, Wanping Xu, Sara C McGrath, et al.
Future Medicinal Chemistry|June 6, 2013
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivityAnnerleim Walton-Diaz, Sahar Khan, Dimitra Bourboulia, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2006
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activationFumitaka Koga, Wanping Xu, Tatiana S Karpova, et al.
International Journal of Cancer|October 4, 2011
Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cellsManabu Tatokoro, Fumitaka Koga, Soichiro Yoshida, et al.
Current Topics in Medicinal Chemistry|April 14, 2016
Targeting Hsp90 in Non-Cancerous MaladiesMark R Woodford, Diana M Dunn, Joseph G Ciciarelli, et al.
Pageof 17